NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Lisata Therapeutics, Inc. LSTA
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$170,000
▼ 83.0% vs FY2024
EPS · FY25
$-1.91
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-74.7%
Net margin · FY25
-9756.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 170,000.00
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 9756 cents on every revenue dollar this year.
Per share
USD -1.91
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-74.7%
Return on equity, FY2025
ROE
Operating margin-10711.2%
Net margin-9756.5%
Return on assets-62.9%
Each USD of equity lost 75 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−38.6%
−33.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 17.7M
total assets, end of FY2025
Total assetsUSD 17.7M
EquityUSD 14.9M
CashUSD 16.0M
Current ratio5.76×
Equity funds 84% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.1
Operating income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
·
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.1
−0.1
−0.0
−0.1
−0.0
−0.0
EPS, diluted $
−1.91
−2.40
−2.58
−10.47
−7.45
−0.53
−1.88
−1.67
2.56
−4.99
−16.67
−1.68
−1.90
−4.00
−0.54
−0.46
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
−0
−0
−1
−0
−1
ROE %
−74.7
−51.4
−36.3
−68.3
−44.0
−30.6
−66.1
−36.6
83.0
−228.4
−197.0
−91.6
−82.5
−113.0
−85.2
−47.9
Shares out B
0.01
0.01
0.01
0.01
0.00
0.02
0.01
0.01
0.01
0.01
0.01
0.04
0.03
0.02
0.11
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 46
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed